383 related articles for article (PubMed ID: 17312675)
1. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL
J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675
[TBL] [Abstract][Full Text] [Related]
2. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
3. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin.
Gosriwatana I; Loreal O; Lu S; Brissot P; Porter J; Hider RC
Anal Biochem; 1999 Sep; 273(2):212-20. PubMed ID: 10469492
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
[TBL] [Abstract][Full Text] [Related]
5. Myocardial release of non-transferrin-bound iron during cardio-pulmonary bypass surgery.
Ambrus CM; Lajos TZ; Stadler I; Stadler A; Alfano J; Tulumello JA; Ambrus JL
J Med; 1999; 30(3-4):157-67. PubMed ID: 17312669
[TBL] [Abstract][Full Text] [Related]
6. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
7. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
Blood; 2001 Feb; 97(3):792-8. PubMed ID: 11157499
[TBL] [Abstract][Full Text] [Related]
8. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
Breuer W; Ronson A; Slotki IN; Abramov A; Hershko C; Cabantchik ZI
Blood; 2000 May; 95(9):2975-82. PubMed ID: 10779448
[TBL] [Abstract][Full Text] [Related]
9. Non-transferrin-bound iron in platelet concentrates promotes the growth of Staphylococcus epidermidis.
Matinaho S; Parkkinen J
Transfusion; 2005 Jun; 45(6):927-33. PubMed ID: 15934991
[TBL] [Abstract][Full Text] [Related]
10. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
[TBL] [Abstract][Full Text] [Related]
11. High nontransferrin bound iron levels and heart disease in thalassemia major.
Piga A; Longo F; Duca L; Roggero S; Vinciguerra T; Calabrese R; Hershko C; Cappellini MD
Am J Hematol; 2009 Jan; 84(1):29-33. PubMed ID: 19006228
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence assay of non-transferrin-bound iron in thalassemic sera using bacterial siderophore.
Sharma M; Saxena R; Gohil NK
Anal Biochem; 2009 Nov; 394(2):186-91. PubMed ID: 19632191
[TBL] [Abstract][Full Text] [Related]
13. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
[TBL] [Abstract][Full Text] [Related]
14. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform.
Jacobs EM; Hendriks JC; van Tits BL; Evans PJ; Breuer W; Liu DY; Jansen EH; Jauhiainen K; Sturm B; Porter JB; Scheiber-Mojdehkar B; von Bonsdorff L; Cabantchik ZI; Hider RC; Swinkels DW
Anal Biochem; 2005 Jun; 341(2):241-50. PubMed ID: 15907869
[TBL] [Abstract][Full Text] [Related]
15. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S
Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
[TBL] [Abstract][Full Text] [Related]
16. Can iron chelators influence the progression of atherosclerosis?
Marx JJ; Kartikasari AE; Georgiou NA
Hemoglobin; 2008; 32(1-2):123-34. PubMed ID: 18274990
[TBL] [Abstract][Full Text] [Related]
17. Non-transferrin bound iron: a key role in iron overload and iron toxicity.
Brissot P; Ropert M; Le Lan C; Loréal O
Biochim Biophys Acta; 2012 Mar; 1820(3):403-10. PubMed ID: 21855608
[TBL] [Abstract][Full Text] [Related]
18. Sensitive method for nontransferrin-bound iron quantification by graphite furnace atomic absorption spectrometry.
Jakeman A; Thompson T; McHattie J; Lehotay DC
Clin Biochem; 2001 Feb; 34(1):43-7. PubMed ID: 11239514
[TBL] [Abstract][Full Text] [Related]
19. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
Breuer W; Ghoti H; Shattat A; Goldfarb A; Koren A; Levin C; Rachmilewitz E; Cabantchik ZI
Am J Hematol; 2012 Jan; 87(1):55-61. PubMed ID: 22125177
[TBL] [Abstract][Full Text] [Related]
20. Nontransferrin-bound iron in transfused patients with sickle cell disease.
Inati A; Musallam KM; Cappellini MD; Duca L; Taher AT
Int J Lab Hematol; 2011 Apr; 33(2):133-7. PubMed ID: 21382180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
